Secondary adrenal insufficiency
diseaseOn this page
Also known as central adrenal insufficiencycentral Hypoadrenalismhypocortisolism secondary to another disorder
Summary
Secondary adrenal insufficiency (MONDO:0043370) is a disease and 6 clinical trials. Top therapeutic interventions include fludrocortisone acetate, hydrocortisone, and mifepristone. A subtype of adrenocortical insufficiency — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 6
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | secondary adrenal insufficiency |
| Mondo ID | MONDO:0043370 |
| NCIT | C62602 |
| SNOMED CT | 16685009 |
| UMLS | C0948387 |
| MedGen | 184925 |
| Is cancer (heuristic) | no |
Also known as: central adrenal insufficiency · central Hypoadrenalism · hypocortisolism secondary to another disorder · secondary adrenal insufficiency
Disease family
This is a subtype of adrenocortical insufficiency. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › endocrine system disorder › adrenal gland disorder › adrenal cortex disorder › adrenocortical insufficiency › secondary adrenal insufficiency
Related subtypes (1): primary adrenal insufficiency
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 6.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 3 |
| PHASE4 | 2 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06832566 | PHASE4 | NOT_YET_RECRUITING | Ramadan Fasting Outcomes in Patients With Secondary Adrenal Insufficiency Before and After the Treatment of Hypotension. |
| NCT02277587 | PHASE4 | COMPLETED | Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) |
| NCT04588688 | PHASE2 | TERMINATED | Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency |
| NCT00561236 | Not specified | COMPLETED | Does Intravitreal Injection of Triamcinolone Acetonide Impairs the Adrenal Function |
| NCT04700644 | Not specified | COMPLETED | Assessment of CAI in Adults With PWS. |
| NCT05827965 | Not specified | COMPLETED | Ramadan Fasting in Secondary Adrenal Insufficiency Patients |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FLUDROCORTISONE ACETATE | 4 | 1 |
| HYDROCORTISONE | 4 | 1 |
| MIFEPRISTONE | 4 | 1 |
| FLUDROCORTISONE | 2 | 1 |
| CHEMBL4740452 | 0 | 1 |